Pancragen

Primary Benefits

• Supports pancreatic endocrine function
• Helps support healthy glucose metabolism and insulin signaling
• Supports balanced insulin and C-peptide dynamics in aging pancreas research
• Promotes metabolic balance and pancreatic cellular resilience
• Commonly used for pancreatic support and age-related metabolic research

Mechanism of Action

Pancragen is a tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Trp (KEDW). It is studied as a pancreas-focused bioregulator, particularly for age-related changes in endocrine pancreatic function. In old rhesus monkeys, Pancragen administration improved glucose disappearance after glucose challenge and helped normalize insulin and C-peptide dynamics, with some effects persisting after discontinuation. Additional bioregulator research suggests Pancragen influences transcription factors involved in pancreatic cell differentiation and islet function, supporting its use in glucose-metabolism and pancreatic-aging research.

Dosing & Protocol

Subcutaneous (SQ) Injection (preferred)

Reconstitution:

-20 mg vial → 2.0 ml bacteriostatic water

Daily Dose:

-500 mcg–1 mg (5–10 units)

Cycle:

-Daily for 10–20 days; repeat 1–3 times yearly as needed or as directed by your healthcare provider

Timing:

-Morning, ideally before food

Potential Side Effects

• Injection-site redness, tenderness, itching, or mild swelling
• Headache, nausea, lightheadedness, or mild digestive upset
• Changes in appetite, energy, or perceived blood-sugar stability
• Possible low-blood-sugar symptoms in sensitive individuals or those using glucose-lowering medications
• Rare: severe abdominal pain, vomiting, allergic reaction, or concerning pancreatic symptoms; seek medical care

If side effects occur, users commonly reduce dose or discontinue use and consult a healthcare professional.

Common Stacks

• With Livagen: For liver, pancreas, and metabolic bioregulator support
• With MOTS-C: For mitochondrial and glucose-metabolism research
• With KPV: For gut-barrier and inflammatory balance protocols
• With AOD9604 / 5-Amino-1MQ: For body-composition and metabolic support protocols

Notes

• Injection is subcutaneous into the lower abdomen or another standard SQ site (such as the outer thigh or upper buttock).
• Pancragen is not a replacement for insulin, diabetes medication, diet, glucose monitoring, or medical care.
• Individuals using insulin, sulfonylureas, GLP-1/GIP medications, or other glucose-lowering therapies should use extra caution and clinician guidance.
• Lyophilized (dry) Pancragen vials should be stored in the freezer.
• After reconstitution, store in the refrigerator and use within 45 days unless the product label or protocol says otherwise.
• Tracking fasting glucose, post-meal glucose, A1c, insulin, and C-peptide can help clarify response in supervised protocols.

References

Impact of tetrapeptide Pancragen on endocrine function of the pancreas in old monkeys (Goncharova et al., 2015, PubMed)

Link: https://pubmed.ncbi.nlm.nih.gov/25946840/

Efficacy of Pancragen peptide in elderly patients with type 2 diabetes mellitus (Korkushko et al., 2010)

Link: https://jpep.endocrinology.org.ua/index.php/1/article/view/789

Peptides tissue-specifically stimulate cell differentiation during aging (Khavinson et al., 2012, PubMed)

Link: https://pubmed.ncbi.nlm.nih.gov/22808515/

Effects of Pancragen on differentiation of pancreatic cells during ageing (Khavinson et al., 2013, PubMed)

Link: https://pubmed.ncbi.nlm.nih.gov/23486591/

Disclaimer

The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.